Latest news and press releases about Eupraxia Pharmaceuticals Inc. (EPRX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. Its proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need.
Price
| Price | $8.09 |
| Market Cap | $271M |
| Exchange | NASDAQ |
| Country | CA |
Valuation Ratios
| Price / Book | 4.72 |
| EV / EBITDA | -3.94 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -45.29% |
| Return on Invested Capital | -43.07% |
| Return on Assets | -35.72% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: AARD · GNFT · IVA · MDWD · NAUT · NTHI · OBIO
Explore sector: Healthcare · Biotechnology
More sections of EPRX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks